1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Analysis of clinical outcomes according to response status in prospective clinical trials of atezolizumab (atezo) in pretreated locally advanced/metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Bedke, J.; Merseburger, A. S.; Loriot, Y.; Castellano, D.; Choy, E.; Duran, I.; Rosenberg, J. E.; Petrylak, D. P.; Dreicer, R.; Perez-Gracia, J. L.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Association of circulating tumor cell chromosomal instability with worse outcomes in men with mCRPC treated with abiraterone or enzalutamide
    Meeting Abstract

    Brown, L. C.; Halabi, S.; Schonhoft, J.; Luo, J.; Nanus, D. M.; Giannakakou, P.; Szmulewitz, R. Z.; Danila, D. C.; Healy, P.; Anand, M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase II study assessing the safety and efficacy of ASP1650 in male patients with incurable platinum refractory germ cell tumors
    Meeting Abstract

    Adra, N.; Vaughn, D. J.; Einhorn, L.; Hanna, N. H.; Rosales, M.; Arozullah, A.; Feldman, D. R.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Association of radical cystectomy and increased risk of skeletal-related events in bone-metastatic urothelial carcinoma
    Meeting Abstract

    Almassi, N.; Easthausen, I. J.; Ghafoor, S.; Christos, P. J.; Donahue, T. F.; Rosenberg, J. E.; Farooki, A.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Checkpoint kinase inhibition in prostate cancer cells resistant to poly ADP-ribose polymerase inhibitors
    Meeting Abstract

    Atiq, M. O.; Chakraborty, G.; Nandakumar, S.; Mazzu, Y. Z.; Stopsack, K. H.; Yoshikawa, Y.; Lee, G. S. M.; Kantoff, P. W.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • The spinal distribution of metastatic renal cell carcinoma: Support for locoregional rather than arterial hematogenous mode of early bony dissemination
    Meeting Abstract

    Attalla, K.; Duzgol, C.; McLaughlin, L.; Flynn, J.; Ostrovnaya, I.; DiNatale, R. G.; Silagy, A. W.; Coleman, J.; Lee, C. H.; Carlo, M. I.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Prevalence and landscape of actionable genomic alterations in renal cell carcinoma
    Meeting Abstract

    Attalla, K.; DiNatale, R. G.; Reznik, E.; Fong, C.; Sanchez-Vega, F.; Silagy, A. W.; Weng, S.; Coleman, J.; Lee, C. H.; Carlo, M. I.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • AR-V7 and prediction of benefit with taxane therapy: Final analysis of PROPHECY
    Meeting Abstract

    Armstrong, A. J.; Luo, J.; Anand, M.; Antonarakis, E. S.; Nanus, D. M.; Giannakakou, P.; Szmulewitz, R. Z.; Danila, D. C.; Healy, P.; Berry, W. R.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase Ib/II open-label study of tazemetostat (TAZ) plus enzalutamide (E) or abiraterone/prednisone (A/P) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Abida, W.; Bradley, T. P.; Rezazadeh, A.; Karsh, L. I.; Ross, A.; Saltzstein, D.; Argon, E. K.; Hamlett, A.; Tang, J.; Adib, D.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Avelumab flat dose regimen: Justification for use in advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Haanen, J. B. A. G.; Masters, J. C.; Huang, B.; Choueiri, T. K.; Motzer, R. J.; Khandelwal, A.; Dai, H.; di Pietro, A.; Brar, S.; Rini, B. I.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save